{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:19:40Z","timestamp":1794835180761,"version":"4.9.1"},"reference-count":93,"publisher":"Elsevier","isbn-type":[{"value":"9780443417610","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.ircmb.2026.02.005","type":"book-chapter","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:34:36Z","timestamp":1771936476000},"page":"225-245","source":"Crossref","is-referenced-by-count":0,"title":["IL-23 blockade: A strategy for managing pain-related inflammatory diseases"],"prefix":"10.1016","author":[{"given":"Mario","family":"Garc\u00eda-Dom\u00ednguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/bs.ircmb.2026.02.005_bib1","first-page":"449","article-title":"ASICs mediate pain and inflammation in musculoskeletal diseases","volume":"30","author":"Abdelhamid","year":"2015","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/bs.ircmb.2026.02.005_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/26331055231220340","article-title":"A comprehensive review on the regulatory action of TRP channels: A potential therapeutic target for nociceptive pain","volume":"18","author":"Anand","year":"2023","journal-title":"Neuroscience Insights"},{"issue":"2","key":"10.1016\/bs.ircmb.2026.02.005_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cell.2009.09.028","article-title":"Cellular and molecular mechanisms of pain","volume":"139","author":"Basbaum","year":"2009","journal-title":"Cell"},{"issue":"3","key":"10.1016\/bs.ircmb.2026.02.005_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1016\/bs.ircmb.2026.02.005_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.immuni.2017.12.008","article-title":"Structural activation of pro-inflammatory human cytokine IL-23 by cognate IL-23 receptor enables recruitment of the shared receptor IL-12R\u03b21","volume":"48","author":"Bloch","year":"2018","journal-title":"Immunity"},{"issue":"14","key":"10.1016\/bs.ircmb.2026.02.005_bib6","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.3390\/ijms20143394","article-title":"Th17 cells and the IL-23\/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases","volume":"20","author":"Bunte","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/bs.ircmb.2026.02.005_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41392-024-01845-w","article-title":"Pathology of pain and its implications for therapeutic interventions","volume":"9","author":"Cao","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"11","key":"10.1016\/bs.ircmb.2026.02.005_bib8","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1080\/21645515.2018.1461297","article-title":"Immunotherapy in inflammatory bowel disease: Novel and emerging treatments","volume":"14","author":"Catalan-Serra","year":"2018","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"5","key":"10.1016\/bs.ircmb.2026.02.005_bib9","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1159\/000354525","article-title":"IL-17A induces pro-inflammatory cytokines production in macrophages via MAPKinases, NF-\u03baB and AP-1","volume":"32","author":"Chen","year":"2013","journal-title":"Cellular Physiology and Biochemistry"},{"issue":"3","key":"10.1016\/bs.ircmb.2026.02.005_bib10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.it.2017.12.003","article-title":"Immune cytokines and their receptors in inflammatory pain","volume":"39","author":"Cook","year":"2018","journal-title":"Trends in Immunology"},{"issue":"6","key":"10.1016\/bs.ircmb.2026.02.005_bib11","doi-asserted-by":"crossref","first-page":"R194","DOI":"10.1186\/ar2893","article-title":"Interleukin-23 is critical for full-blown expression of a non-autoimmune destructive arthritis and regulates interleukin-17A and RORgammat in gamma delta T cells","volume":"11","author":"Cornelissen","year":"2009","journal-title":"Arthritis Research & Therapy"},{"issue":"2","key":"10.1016\/bs.ircmb.2026.02.005_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057553","article-title":"IL-23 Dependent and independent stages of experimental arthritis: No clinical effect of therapeutic IL-23p19 inhibition in collagen-induced arthritis","volume":"8","author":"Cornelissen","year":"2013","journal-title":"PLoS One"},{"issue":"6924","key":"10.1016\/bs.ircmb.2026.02.005_bib13","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2026.02.005_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.984678","article-title":"The immune system as a system of relations","volume":"13","author":"Da\u00ebron","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/bs.ircmb.2026.02.005_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn\u2019s disease: Maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"The Lancet Gastroenterology and Hepatology"},{"issue":"11","key":"10.1016\/bs.ircmb.2026.02.005_bib16","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/ecco-jcc\/jjae088","article-title":"Early and sustained symptom control with mirikizumab in patients with ulcerative colitis in the phase 3 LUCENT programme","volume":"18","author":"Danese","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"10340","key":"10.1016\/bs.ircmb.2026.02.005_bib17","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: Results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D\u2019Haens","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/bs.ircmb.2026.02.005_bib18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/s13075-014-0496-y","article-title":"Leukotriene B4 activates intracellular calcium and augments human osteoclastogenesis","volume":"16","author":"Dixit","year":"2014","journal-title":"Arthritis Research & Therapy"},{"issue":"1","key":"10.1016\/bs.ircmb.2026.02.005_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/mi.2013.33","article-title":"IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism","volume":"7","author":"Eken","year":"2014","journal-title":"Mucosal Immunology"},{"issue":"10340","key":"10.1016\/bs.ircmb.2026.02.005_bib20","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: Results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"issue":"10470","key":"10.1016\/bs.ircmb.2026.02.005_bib21","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: A phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/bs.ircmb.2026.02.005_bib22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cytogfr.2015.07.005","article-title":"Insights into IL-23 biology: From structure to function","volume":"26","author":"Floss","year":"2015","journal-title":"Cytokine & Growth Factor Reviews"},{"key":"10.1016\/bs.ircmb.2026.02.005_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2024.1477017","article-title":"Chronic pain in the elderly: Exploring cellular and molecular mechanisms and therapeutic perspectives","volume":"5","author":"Garc\u00eda-Dom\u00ednguez","year":"2024","journal-title":"Frontiers in Aging"},{"issue":"4","key":"10.1016\/bs.ircmb.2026.02.005_bib24","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.cell.2021.01.018","article-title":"Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells","volume":"184","author":"Glassman","year":"2021","journal-title":"Cell"},{"issue":"10148","key":"10.1016\/bs.ircmb.2026.02.005_bib25","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/bs.ircmb.2026.02.005_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.mpaic.2022.04.002","article-title":"The anatomy of pain","volume":"23","author":"Gore","year":"2022","journal-title":"Anaesthesia & Intensive Care Medicine"},{"issue":"2","key":"10.1016\/bs.ircmb.2026.02.005_bib27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/COH.0b013e328335c2f6","article-title":"Th17 cytokines in mucosal immunity and inflammation","volume":"5","author":"Guglani","year":"2010","journal-title":"Current Opinion in HIV and AIDS"},{"issue":"3","key":"10.1016\/bs.ircmb.2026.02.005_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuron.2007.07.008","article-title":"Signaling pathways in sensitization: Toward a nociceptor cell biology","volume":"55","author":"Hucho","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/bs.ircmb.2026.02.005_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.787565","article-title":"IL-23 Enhances C-fiber-mediated and blue light-induced spontaneous pain in female mice","volume":"12","author":"Ji","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/bs.ircmb.2026.02.005_bib30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/ALN.0000000000002130","article-title":"Neuroinflammation and central sensitization in chronic and widespread pain","volume":"129","author":"Ji","year":"2018","journal-title":"Anesthesiology"},{"issue":"23","key":"10.1016\/bs.ircmb.2026.02.005_bib31","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.3390\/ijms20236008","article-title":"Cytokines in inflammatory disease","volume":"20","author":"Kany","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"10.1016\/bs.ircmb.2026.02.005_bib32","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1189\/jlb.1005556","article-title":"Paneth cells: Leukocyte-like mediators of innate immunity in the intestine","volume":"80","author":"Keshav","year":"2006","journal-title":"Journal of Leukocyte Biology"},{"issue":"3","key":"10.1016\/bs.ircmb.2026.02.005_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2174\/156802607779941314","article-title":"Eicosanoids in inflammation: Biosynthesis, pharmacology, and therapeutic frontiers","volume":"7","author":"Khanapure","year":"2007","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"1","key":"10.1016\/bs.ircmb.2026.02.005_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/bja\/87.1.3","article-title":"Mechanisms of inflammatory pain","volume":"87","author":"Kidd","year":"2001","journal-title":"British Journal of Anaesthesia"},{"issue":"2","key":"10.1016\/bs.ircmb.2026.02.005_bib35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archdermatol.2007.63","article-title":"Safety and efficacy of ABT-874, a fully human interleukin 12\/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: Results of a randomized, placebo-controlled, phase 2 trial","volume":"144","author":"Kimball","year":"2008","journal-title":"Archives of Dermatological Research"},{"issue":"7","key":"10.1016\/bs.ircmb.2026.02.005_bib36","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1097\/j.pain.0000000000000507","article-title":"Do we need a third mechanistic descriptor for chronic pain states?","volume":"157","author":"Kosek","year":"2016","journal-title":"Pain"},{"key":"10.1016\/bs.ircmb.2026.02.005_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1331217","article-title":"IL-23 past, present, and future: A roadmap to advancing IL-23 science and therapy","volume":"15","author":"Krueger","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"10.1016\/bs.ircmb.2026.02.005_bib38","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1136\/gutjnl-2014-309014","article-title":"Tissue-infiltrating neutrophils represent the main source of IL-23 in the colon of patients with IBD","volume":"65","author":"Kvedaraite","year":"2016","journal-title":"Gut"},{"issue":"1","key":"10.1016\/bs.ircmb.2026.02.005_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.chembiol.2021.05.002","article-title":"Probing the binding of interleukin-23 to individual receptor components and the IL-23 heteromeric receptor complex in living cells using NanoBRET","volume":"29","author":"Lay","year":"2023","journal-title":"Cell Chemical Biology"},{"issue":"2","key":"10.1016\/bs.ircmb.2026.02.005_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cps.2019.11.001","article-title":"Pain: Pathways and physiology","volume":"47","author":"Lee","year":"2020","journal-title":"Clinics in Plastic Surgery"},{"issue":"1","key":"10.1016\/bs.ircmb.2026.02.005_bib41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13075-020-02212-0","article-title":"IL-23 in arthritic and inflammatory pain development in mice","volume":"22","author":"Lee","year":"2020","journal-title":"Arthritis Research & Therapy"},{"issue":"1","key":"10.1016\/bs.ircmb.2026.02.005_bib42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-022-02777-y","article-title":"The role of interleukin (IL)-23 in regulating pain in arthritis","volume":"24","author":"Lee","year":"2022","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/bs.ircmb.2026.02.005_bib43","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fphar.2013.00142","article-title":"Immunotherapy targeting cytokines in neuropathic pain","volume":"4","author":"Lees","year":"2013","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"10.1016\/bs.ircmb.2026.02.005_bib44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s13311-015-0401-7","article-title":"Immunotherapy in peripheral neuropathies","volume":"13","author":"L\u00e9ger","year":"2016","journal-title":"Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics"},{"issue":"9625","key":"10.1016\/bs.ircmb.2026.02.005_bib45","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2026.02.005_bib46","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cyto.2019.02.018","article-title":"IL-23 and dendritic cells: What are the roles of their mutual attachment in immune response and immunotherapy?","volume":"120","author":"Li","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/bs.ircmb.2026.02.005_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 pathway in inflammatory skin diseases: From bench to bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"10.1016\/bs.ircmb.2026.02.005_bib48","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/j.pain.0000000000000917","article-title":"Peripheral inflammatory pain sensitisation is independent of mast cell activation in male mice","volume":"158","author":"Lopes","year":"2017","journal-title":"Pain"},{"issue":"11","key":"10.1016\/bs.ircmb.2026.02.005_bib49","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: Two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA: the Journal of the American Medical Association"},{"issue":"4","key":"10.1016\/bs.ircmb.2026.02.005_bib50","doi-asserted-by":"crossref","first-page":"iv16","DOI":"10.1093\/rheumatology\/keab385","article-title":"Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints","volume":"60","author":"\u0141ukasik","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"17","key":"10.1016\/bs.ircmb.2026.02.005_bib51","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/j.neuron.2021.06.015","article-title":"IL-23\/IL-17A\/TRPV1 axis produces mechanical pain via macrophage-sensory neuron crosstalk in female mice","volume":"109","author":"Luo","year":"2021","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/bs.ircmb.2026.02.005_bib52","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jmb.2008.07.051","article-title":"The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12","volume":"382","author":"Lupardus","year":"2008","journal-title":"Journal of Molecular Biology"},{"issue":"9894","key":"10.1016\/bs.ircmb.2026.02.005_bib53","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/bs.ircmb.2026.02.005_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250348","article-title":"Interleukin 23 receptor: Expression and regulation in immune cells","volume":"54","author":"Mezghiche","year":"2024","journal-title":"European Journal of Immunology"},{"issue":"12","key":"10.1016\/bs.ircmb.2026.02.005_bib55","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"Journal of Experimental Medicine"},{"issue":"6","key":"10.1016\/bs.ircmb.2026.02.005_bib56","first-page":"1329","article-title":"Briakinumab for treatment of Crohn\u2019s disease: Results of a randomized trial","volume":"21","author":"Panaccione","year":"2015","journal-title":"Inflammatory Bowel Diseases"},{"issue":"11","key":"10.1016\/bs.ircmb.2026.02.005_bib57","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.15252\/embr.201744200","article-title":"IL-23 Drives differentiation of peripheral \u03b3\u03b417 T cells from adult bone marrow-derived precursors","volume":"18","author":"Papotto","year":"2017","journal-title":"EMBO Reports"},{"issue":"9625","key":"10.1016\/bs.ircmb.2026.02.005_bib58","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/bs.ircmb.2026.02.005_bib59","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.3390\/cells9092044","article-title":"Decoding IL-23 signaling cascade for new therapeutic opportunities","volume":"9","author":"Pastor-Fern\u00e1ndez","year":"2020","journal-title":"Cells"},{"key":"10.1016\/bs.ircmb.2026.02.005_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1072629","article-title":"Neuropathic pain: Mechanisms and therapeutic strategies","volume":"11","author":"Petroianu","year":"2023","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"6","key":"10.1016\/bs.ircmb.2026.02.005_bib61","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study","volume":"165","author":"Peyrin-Biroulet","year":"2023","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/bs.ircmb.2026.02.005_bib62","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.4049\/jimmunol.176.3.1908","article-title":"In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin","volume":"176","author":"Piskin","year":"2006","journal-title":"The Journal of Immunology"},{"issue":"5","key":"10.1016\/bs.ircmb.2026.02.005_bib63","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: Results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1016\/bs.ircmb.2026.02.005_bib64","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1097\/j.pain.0000000000001939","article-title":"The revised international association for the study of pain definition of pain: Concepts, challenges, and compromises","volume":"161","author":"Raja","year":"2020","journal-title":"Pain"},{"issue":"11","key":"10.1016\/bs.ircmb.2026.02.005_bib65","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.21037\/jtd-2019-cptn-10","article-title":"Immunotherapy in patients with autoimmune disease","volume":"12","author":"Rakshit","year":"2020","journal-title":"Journal of Thoracic Disease"},{"issue":"6","key":"10.1016\/bs.ircmb.2026.02.005_bib66","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1016\/bs.ircmb.2026.02.005_bib67","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn\u2019s disease: Induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/bs.ircmb.2026.02.005_bib68","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1152\/physrev.00025.2008","article-title":"Models and mechanisms of hyperalgesia and allodynia","volume":"89","author":"Sandk\u00fchler","year":"2009","journal-title":"Physiological Reviews"},{"issue":"2","key":"10.1016\/bs.ircmb.2026.02.005_bib69","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn\u2019s disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/bs.ircmb.2026.02.005_bib70","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1533-2500.2010.00358.x","article-title":"Transient receptor potential channels in pain and inflammation: Therapeutic opportunities","volume":"10","author":"Schumacher","year":"2010","journal-title":"Pain Practice"},{"issue":"1","key":"10.1016\/bs.ircmb.2026.02.005_bib71","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/1744666X.2019.1544493","article-title":"Tildrakizumab for the treatment of psoriasis","volume":"15","author":"Sinclair","year":"2019","journal-title":"Expert Review of Clinical Immunology"},{"issue":"4","key":"10.1016\/bs.ircmb.2026.02.005_bib72","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: A retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"The Lancet Rheumatology"},{"issue":"5","key":"10.1016\/bs.ircmb.2026.02.005_bib73","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2016-209831","article-title":"A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate","volume":"76","author":"Smolen","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1016\/bs.ircmb.2026.02.005_bib74","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.4049\/jimmunol.181.9.5948","article-title":"IL-23 promotes maintenance but not commitment to the Th17 lineage","volume":"181","author":"Stritesky","year":"2008","journal-title":"Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.ircmb.2026.02.005_bib75","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5313\/wja.v3.i1.71","article-title":"Molecular mechanism of inflammatory pain","volume":"3","author":"Su","year":"2014","journal-title":"World Journal of Anesthesiology"},{"issue":"3","key":"10.1016\/bs.ircmb.2026.02.005_bib76","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/aps.2011.200","article-title":"Role of G protein-coupled receptors in inflammation","volume":"33","author":"Sun","year":"2012","journal-title":"Acta Pharmacologica Sinica"},{"issue":"4","key":"10.1016\/bs.ircmb.2026.02.005_bib77","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.biocel.2008.04.027","article-title":"Interleukin-23: Immunological roles and clinical implications","volume":"41","author":"Tan","year":"2009","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"4","key":"10.1016\/bs.ircmb.2026.02.005_bib78","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12264-021-00797-3","article-title":"The macrophage IL-23\/IL-17A pathway: A new neuro-immune mechanism in female mechanical pain","volume":"38","author":"Tan","year":"2022","journal-title":"Neuroscience Bulletin"},{"issue":"20","key":"10.1016\/bs.ircmb.2026.02.005_bib79","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"10155","key":"10.1016\/bs.ircmb.2026.02.005_bib80","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: Results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/bs.ircmb.2026.02.005_bib81","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3899\/jrheum.210805","article-title":"Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: Results of a phase II open-label extension study","volume":"49","author":"van Vollenhoven","year":"2022","journal-title":"The Journal of Rheumatology"},{"issue":"11","key":"10.1016\/bs.ircmb.2026.02.005_bib82","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"van Vollenhoven","year":"2022","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1016\/bs.ircmb.2026.02.005_bib83","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: Immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nature Immunology"},{"issue":"11","key":"10.1016\/bs.ircmb.2026.02.005_bib84","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nature Reviews. Immunology"},{"issue":"3","key":"10.1016\/bs.ircmb.2026.02.005_bib85","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1021\/acschemneuro.1c00607","article-title":"A novel progress: Glial cells and inflammatory pain","volume":"13","author":"Wang","year":"2022","journal-title":"ACS Chemical Neuroscience Journal"},{"key":"10.1016\/bs.ircmb.2026.02.005_bib86","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.25.022106.141557","article-title":"IL-17 Family cytokines and the expanding diversity of effector T cell lineages","volume":"25","author":"Weaver","year":"2007","journal-title":"Annual Review of Immunology"},{"issue":"2","key":"10.1016\/bs.ircmb.2026.02.005_bib87","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2009.11.003","article-title":"N-Methyl-D-aspartate receptor (NMDAR) independent maintenance of inflammatory pain","volume":"148","author":"Weyerbacher","year":"2010","journal-title":"Pain"},{"key":"10.1016\/bs.ircmb.2026.02.005_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.982238","article-title":"The regulatory mechanism and potential application of IL-23 in autoimmune diseases","volume":"13","author":"Xiong","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"10.1016\/bs.ircmb.2026.02.005_bib89","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/ACO.0b013e32834871df","article-title":"A brief comparison of the pathophysiology of inflammatory versus neuropathic pain","volume":"24","author":"Xu","year":"2011","journal-title":"Current Opinion in Anesthesiology"},{"issue":"3","key":"10.1016\/bs.ircmb.2026.02.005_bib90","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1021\/acs.jchemed.5b00404","article-title":"RCSB protein data bank: A resource for chemical, biochemical, and structural explorations of large and small biomolecules","volume":"93","author":"Zardecki","year":"2016","journal-title":"Journal of Chemical Education"},{"issue":"7","key":"10.1016\/bs.ircmb.2026.02.005_bib91","article-title":"Advances in systemic lupus erythematosus treatment with monoclonal antibodies: A mini-review","volume":"16","author":"Zavaleta-Monestel","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/bs.ircmb.2026.02.005_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108476","article-title":"Immunotherapies in chronic pain through modulation of neuroimmune interactions","volume":"248","author":"Zhao","year":"2023","journal-title":"Pharmacology & Therapeutics"},{"issue":"5","key":"10.1016\/bs.ircmb.2026.02.005_fur1","first-page":"872","article-title":"Pain and bone damage in rheumatoid arthritis: Role of leukotriene B4","volume":"37","author":"Zheng","year":"2024","journal-title":"Clinical and Experimental Rheumatology"}],"container-title":["International Review of Cell and Molecular Biology","Cytokine-based immunotherapy - Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644826000079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644826000079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:30:38Z","timestamp":1779204638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644826000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443417610"],"references-count":93,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2026.02.005","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}